Newsroom

News

Antibiotics are a double-edged sword – they should be as toxic as possible to pathogenic bacteria while being harmless to the cells of the human body. An international research team led by the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now developed drug candidates that achieve precisely that. The new molecules target a metabolic pathway that only occurs in bacterial cells, thus sparing human cells. The team published its results in the journal Angewandte Chemie International Edition.

13.01.2025

HIPS

Atomic model of Bacteroides thetaiotaomicron RbpB protein with individual B. thetaiotaomicron bacteria in the background

News

Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius-Maximilians-Universität (JMU) in Würzburg have identified a protein and a group of small ribonucleic acids (sRNAs) in Bacteroides thetaiotaomicron, which regulate sugar metabolism. These discoveries shed light on how this gut microbe adapts to varying nutritional conditions. The findings deepen our understanding of this bacterium's role in the human gut and may pave the way for new therapeutic strategies to promote health through the microbiota. The study was published in the journal Nature Communications.

09.01.2025

HIRI

News

Researchers at the Helmholtz Centre for Infection Research (HZI) have developed a promising new vaccine technology. Their studies to date show that just one dose of vaccine leads to effective and long-lasting immune protection. The basis of this so-called MCMV vaccine vector technology is the mouse cytomegalovirus (MCMV). It acts as a carrier virus that introduces selected antigens of a pathogen to be vaccinated against into the body. In the follow-up project VIVA-VEK-2, which was launched at the HZI at the beginning of January, a proof-of-concept vaccine candidate against respiratory syncytial virus (RSV) is now to be produced and tested for efficacy and tolerability. The researchers believe that with the new vaccine technology, one vaccine dose could possibly even provide lifelong protection. The project is funded by the GO-Bio initial program of the Federal Ministry of Education and Research (BMBF) over two years with a funding volume of one million euros.

07.01.2025

HZI Campus

HIPS

The Horizon Europe project DEFENDER is exploring new targets for antiviral therapies

News

The interdisciplinary project DEFENDER is developing innovative approaches to combat (re-)emerging viruses. The project, coordinated by the Leibniz Institute of Virology (LIV), is being funded with around eight 9.6 million euros as part of Horizon Europe. Almost 700,000 euros of these will go to Prof. Mark Brönstrup, a researcher at the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection Research (DZIF).

06.01.2025

HZI Campus

News

A research team from the Helmholtz Institute for One Health (HIOH) has investigated the distribution and characteristics of multidrug-resistant bacteria in the Baltic Sea. The findings prove that resistant pathogens occur not only in samples taken from clinical settings but also from the environment. The BMBF-funded study also underlines the importance of an integrated strategy for combatting multidrug resistance that takes equal account of environmental and health protection. The results were published recently in the scientific journal npj Clean Water.

23.12.2024

HIOH

Scanning electron micrograph of Mycobacterium tuberculosis

News

Global migration has increased in recent decades due to war, conflict, persecutions, and natural disasters, but also secondary to increased opportunities related to work or study. A group of international experts that collaborate in the Tuberculosis Network European Trialsgroup (TBnet), led by Heinke Kunst from Queen Mary College of London, Berit Lange from the Epidemiology Department at the Helmholtz Centre for Infection Research (HZI), Christoph Lange from the Research Center Borstel and Anca Vasiliu from Baylor College of Medicine, has now identified the risk for tuberculosis and comorbidities in migrants to the European Union/European Economic Area and the United Kingdom (EU/EEA/&UK).

19.12.2024

HZI Campus

Back to the first page
...
10
11
12
13
...
145

HZI in the media

... er Klinischer Direktor des Helmholz Zentrums für Infektionsforschung (HZI) und Gründungsdirektor des Zentrums für Individualisierte ...

21.08.2025

Deutsche Gesellschaft für Innere Medizin e.V.

Nature Medicine

. The CiiM is a joint institution of the Helmholtz Center for Infection Research (HZI) and Hannover Medical School (MHH).

21.08.2025

Medical Xpress

und damit einhergehenden Erkrankungen zu sein.“

Helmholtz-Zentrum für Infektionsforschung

Originalpublikation:

J. Botey-Bataller, N. van

21.08.2025

Verband Deutscher Biologen e.V.

Now, a team of researchers, led by scientists from the Helmholtz Centre for Infection Research in Germany, has reported that a gene in the

21.08.2025

The Hindu

Cicin-Sain, a viral immunologist at Germany's Helmholtz Centre for Infection Research, is leading the development of a respiratory syncytial

16.08.2025

The Times of India

Instituts für Pharmazeutische Forschung Saarland (HIPS), einem gemeinsamen Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) ...

15.08.2025

Springer Medizin

... Einrichtung betreiben die MHH und das Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig gemeinsam.

In seine ...

15.08.2025

Neue Presse (Hannover)

Medicine Bundesamt für Verbraucherschutz und Lebensmittelsicherheit Helmholtz-Zentrum für Infektionsforschung ARD alpha Universität Würzburg

13.08.2025

Brisant

... Prof. Dr. rer. nat. Dunja Bruder, Helmholtz-Zentrum für Infektionsforschung, Braunschweig und Institut für Med. Mikrobiologie ...

12.08.2025

Deutsches Ärzteblatt

Register now for the HZI-Newsletter

and stay up to date!

Email address

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.

Please enter here the word as displayed in the picture. This is to prevent spamming.*

If you can't read the word, click here.